TX HR1495

Suspends House Rule 13, Section 9(a) to allow the conference committee on Senate Bill 2308 to make changes beyond normal limitations regarding the establishment of a consortium to conduct FDA drug development clinical trials with ibogaine for treatment of opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Restructures the ibogaine clinical trial program by removing the original grant program administered by the Health and Human Services Commission and replacing it with a consortium-based model requiring partnership between a drug developer, institution of higher education, and hospital

Requires consortiums to submit detailed proposals including clinical trial design, FDA approval strategy, breakthrough therapy designation plans, intellectual property arrangements recognizing Texas's commercial interest, and plans for third-party payor approval and uninsured patient access

Mandates 1:1 matching funds from non-state sources before state disbursement, with at least 20% of revenue from intellectual property and commercial rights going to the state, and 25% of that state revenue earmarked for Texas veterans programs

Requires quarterly progress and financial reports from selected consortiums to the commission, with annual reports to the legislature by December 1, and mandates the Health and Human Services Commission begin accepting consortium proposals within 60 days of the bill's effective date